The project focuses on COVID-19 infections after vaccination or re-infections, defining aspects such as the cellular and antibody response elicited by vaccines or COVID-19 recovery, the clinical symptoms of re-infection or infection post vaccination and  the vaccine effectiveness and protection against re-infection.

What are the project objectives?

The objectives of the project are to extend the PREDI-COVID inclusion criteria to focus from September 2021 onwards on infections after vaccination or re-infections, including participants from the ORCHESTRA study (n=2050, previously LVS study).

This project is including

1. participants enrollment
2. sample and data collection
3. sample characterisation

What needs will the project meet?

The project will cover the following unmet needs:

Characterisation of the cellular and antibody responses (type and durability) elicited by vaccines and in uninfected and recovered COVID-19 patients (either vaccinated or not) with an emphasis on the variability of immune responses.	Characterisation of the clinical symptoms in case of re-infection/infection post-vaccination and Long COVID profiles.	Definition of the immune correlates of Protection / Vaccine effectiveness.	Identification of the virological factors involved in viral escape to COVID-19 vaccines and in reinfections
Identification the individual characteristics associated with viral escape to COVID-19 vaccines and in reinfections.	Surveillance of variants.	Vaccination of people with Long COVID.

What population do we target?

COVID-19 vaccination and re-infection

• Close follow-up of past SARS-CoV-2 infection, vaccination status, immune response and new SARS-CoV-2 infections

• Regular biospecimen sampling

• Viral sequencing of any positive case 

• T cell response

• Functional antigen stimulation assay

• ACE inhibition assay

• Clinical, Epidemiological and Sociodemographic determinants & risk factors

• Digital/Vocal biomarkers & PROs

Coordinated by